Price$39.73+0.56 (+1.44%)
01:30 PM07:45 PM
News · 26 weeks79-7%
2026-01-182026-07-12
Mix4490d
- Insider24(55%)
- Other10(23%)
- SEC Filings9(20%)
- Earnings1(2%)
Latest news
25 items- INSIDERPresident and CEO Hanna John Walter Jr exercised 118,000 shares at a strike of $8.20 and sold $4,458,637 worth of shares (118,000 units at $37.79) as part of a pre-agreed trading plan (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Valantine Hannah exercised 28,779 shares at a strike of $14.76 and sold $1,040,243 worth of shares (28,779 units at $36.15) as part of a pre-agreed trading plan (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- PRCareDx to Report Second Quarter 2026 Financial Results on July 30, 2026CareDx, Inc. (NASDAQ:CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx’s Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone, register here. Upon registering, a dial-in number and unique PIN will be provided. About CareDx CareDx is a leading pr
- PRCareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage DeterminationCoverage for Surveillance Testing Affirmed for Early Detection of Allograft Rejection in Kidney, Heart, and Lung CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization of the Medicare Local Coverage Determination (LCD) process related to molecular testing for solid organ allograft rejection. The final policy affirms coverage across CareDx’s transplant surveillance offerings in kidney, heart, and lung. Kidney: The policy affirms coverage of AlloSure® Kidney for surveillance testing for up to six tests in the first-year post-transplant and for up to four tests per year in years two
- INSIDERDirector Goldberg Michael was granted 1,746 shares, increasing direct ownership by 2% to 106,438 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- SECCareDx Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CareDx, Inc. (0001217234) (Filer)
- INSIDERPresident and CEO Hanna John Walter Jr covered exercise/tax liability with 8,511 shares, decreasing direct ownership by 1% to 653,448 units (SEC Form 4) to cover withholding tax4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERSecretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 997 shares, decreasing direct ownership by 0.89% to 111,635 units (SEC Form 4) to satisfy withholding obligation4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERChief Commercial Officer Meng Jessica covered exercise/tax liability with 2,411 shares, decreasing direct ownership by 1% to 168,287 units (SEC Form 4) to satisfy withholding obligation4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERCFO & COO Kennedy Keith covered exercise/tax liability with 2,930 shares, decreasing direct ownership by 1% to 219,924 units (SEC Form 4) to satisfy withholding tax4 - CareDx, Inc. (0001217234) (Issuer)
- PRCareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty OncologyNavDx® is the only Medicare-covered MRD test for HPV-positive Head & Neck and Anal Cancers Expands CareDx’s estimated addressable market to more than $12 billion across transplant, specialty oncology, and cell therapy CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202607015393
- INSIDERPresident and CEO Hanna John Walter Jr exercised 70,000 shares at a strike of $8.20 and sold $1,169,736 worth of shares (40,000 units at $29.24) as part of a pre-agreed trading plan, increasing direct ownership by 5% to 661,959 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- PRCareDx Announces Completion of Sale of Lab Products Business to Eurobio ScientificSharpens focus on U.S. precision medicine Testing Services and Patient & Digital Solutions CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the closing of the previously announced sale of its Lab Products business to Eurobio Scientific. The transaction closed on June 30, 2026 following receipt of required Swedish regulatory clearance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630207907/en/ Under the te
- INSIDERPresident and CEO Hanna John Walter Jr sold $424,877 worth of shares (17,683 units at $24.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 631,959 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Valantine Hannah was granted 9,795 shares and sold $279,728 worth of shares (12,103 units at $23.11) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 36,686 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Cournoyer Christine was granted 9,795 shares, increasing direct ownership by 20% to 58,943 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Riggsbee Richard Bryan was granted 9,795 shares, increasing direct ownership by 33% to 39,312 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Cohen Fred E was granted 9,795 shares, increasing direct ownership by 6% to 165,060 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Gunasekaran Suresh was granted 9,795 shares, increasing direct ownership by 36% to 37,248 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Bickerstaff George was granted 9,795 shares, increasing direct ownership by 7% to 154,061 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Goldberg Michael was granted 9,795 shares, increasing direct ownership by 5% to 195,737 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- PRCareDx Announces Second KOAR Analysis Published in the Journal of the American Society of NephrologyAlloSure® Kidney elevations are associated with increased risk of graft dysfunction and loss in kidney transplant recipients Data support the role of AlloSure® Kidney as a noninvasive tool for longitudinal risk stratification and clinical decision-making CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR), a landmark multi-center study, in the Journal of the American Society of Ne
- INSIDERPresident and CEO Hanna John Walter Jr sold $528,443 worth of shares (21,998 units at $24.02) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 649,642 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- SECCareDx Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - CareDx, Inc. (0001217234) (Filer)
- INSIDERSecretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 1,292 shares, decreasing direct ownership by 1% to 112,632 units (SEC Form 4) (withholding obligation)4 - CareDx, Inc. (0001217234) (Issuer)
CDNA FAQ
7 questionsWhat does CareDx Inc. do?
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of...Where does CDNA stock trade?
CareDx Inc. (CDNA) is listed on NASDAQ.What sector and industry is CDNA in?
CareDx Inc. operates in the Health Care sector, Medical Specialities industry.When did CareDx Inc. go public?
CareDx Inc. (CDNA) completed its IPO in 2014.What are analysts saying about CDNA?
CareDx Inc. has had 8 recent analyst actions on file. The most recent action was from Craig Hallum: Hold with a $2600.00 price target on 2026-01-06. Recent price targets range from $1000.00 to $4000.00.What companies are similar to CDNA?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare CDNA side-by-side with any of them on Quantisnow.How can I track CDNA on Quantisnow?
Quantisnow aggregates CareDx Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CDNA to receive live email and push alerts on every new disclosure.